BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Acquires 9,157 Shares of Regeneron Pharmaceuticals Inc (REGN)

BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp increased its holdings in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 16.1% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 65,862 shares of the biopharmaceutical company’s stock after purchasing an additional 9,157 shares during the quarter. BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp’s holdings in Regeneron Pharmaceuticals were worth $24,761,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in REGN. King Luther Capital Management Corp lifted its holdings in Regeneron Pharmaceuticals by 21.3% in the 3rd quarter. King Luther Capital Management Corp now owns 825 shares of the biopharmaceutical company’s stock valued at $369,000 after purchasing an additional 145 shares in the last quarter. BTIM Corp. lifted its holdings in Regeneron Pharmaceuticals by 14.3% in the 4th quarter. BTIM Corp. now owns 1,200 shares of the biopharmaceutical company’s stock valued at $451,000 after purchasing an additional 150 shares in the last quarter. Nomura Asset Management Co. Ltd. lifted its holdings in Regeneron Pharmaceuticals by 0.9% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 17,010 shares of the biopharmaceutical company’s stock valued at $7,606,000 after purchasing an additional 151 shares in the last quarter. Mutual of America Capital Management LLC lifted its holdings in Regeneron Pharmaceuticals by 1.6% in the 4th quarter. Mutual of America Capital Management LLC now owns 9,692 shares of the biopharmaceutical company’s stock valued at $3,644,000 after purchasing an additional 157 shares in the last quarter. Finally, Private Advisor Group LLC lifted its holdings in Regeneron Pharmaceuticals by 3.8% in the 3rd quarter. Private Advisor Group LLC now owns 4,393 shares of the biopharmaceutical company’s stock valued at $2,059,000 after purchasing an additional 159 shares in the last quarter. Institutional investors and hedge funds own 66.38% of the company’s stock.

How to Become a New Pot Stock Millionaire

Shares of REGN stock opened at $321.29 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18. Regeneron Pharmaceuticals Inc has a 1 year low of $313.53 and a 1 year high of $543.55. The stock has a market cap of $36,064.16, a P/E ratio of 31.13, a price-to-earnings-growth ratio of 1.05 and a beta of 1.54.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The company had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter last year, the company earned $3.04 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 28.9% on a year-over-year basis. equities research analysts forecast that Regeneron Pharmaceuticals Inc will post 19.2 EPS for the current fiscal year.

In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,000 shares of the stock in a transaction that occurred on Wednesday, March 14th. The shares were sold at an average price of $340.00, for a total value of $680,000.00. Following the completion of the sale, the director now owns 14,000 shares of the company’s stock, valued at $4,760,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Joseph L. Goldstein sold 1,000 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $325.60, for a total transaction of $325,600.00. The disclosure for this sale can be found here. Insiders sold 5,000 shares of company stock valued at $1,705,640 in the last ninety days. 10.80% of the stock is owned by corporate insiders.

A number of research analysts have issued reports on REGN shares. BMO Capital Markets set a $444.00 target price on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Monday, November 27th. BTIG Research cut their price objective on shares of Regeneron Pharmaceuticals from $520.00 to $480.00 and set a “buy” rating on the stock in a report on Tuesday, November 28th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a report on Tuesday, November 28th. Citigroup lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $480.00 to $380.00 in a report on Friday, December 1st. Finally, TheStreet lowered shares of Regeneron Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Thursday, November 30th. Four equities research analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $449.49.

WARNING: This article was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was illegally copied and reposted in violation of US and international copyright legislation. The correct version of this article can be read at https://www.tickerreport.com/banking-finance/3295019/british-columbia-investment-management-corp-acquires-9157-shares-of-regeneron-pharmaceuticals-inc-regn.html.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Atlantic Capital  Receiving Somewhat Favorable Press Coverage, Accern Reports
Atlantic Capital Receiving Somewhat Favorable Press Coverage, Accern Reports
Foresight Energy  Receives Daily Media Sentiment Rating of -0.02
Foresight Energy Receives Daily Media Sentiment Rating of -0.02
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Park-Ohio  Stock Price
Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Park-Ohio Stock Price
Ribbon Communications Inc  Receives $7.56 Consensus PT from Analysts
Ribbon Communications Inc Receives $7.56 Consensus PT from Analysts
Analysts Set Progressive Co.  Price Target at $53.43
Analysts Set Progressive Co. Price Target at $53.43
Brokerages Set Fortune Brands Home & Security  Target Price at $73.62
Brokerages Set Fortune Brands Home & Security Target Price at $73.62


© 2006-2018 Ticker Report. Google+.